Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX
Diabetes. 2021 Sep;70(9):1929-1937. doi: 10.2337/dbi21-0001. Epub 2021 Jun 27.
Glucose-dependent insulinotropic polypeptide (GIP) (also known as gastric inhibitory polypeptide) is a hormone produced in the upper gut and secreted to the circulation in response to the ingestion of foods, especially fatty foods. Growing evidence supports the physiological and pharmacological relevance of GIP in obesity. In an obesity setting, inhibition of endogenous GIP or its receptor leads to decreased energy intake, increased energy expenditure, or both, eventually causing weight loss. Further, supraphysiological dosing of exogenous long-lasting GIP agonists alters energy balance and has a marked antiobesity effect. This remarkable yet paradoxical antiobesity effect is suggested to occur primarily via the brain. The brain is capable of regulating both energy intake and expenditure and plays a critical role in human obesity. In addition, the GIP receptor is widely distributed throughout the brain, including areas responsible for energy homeostasis. Recent studies have uncovered previously underappreciated roles of the GIP receptor in the brain in the context of obesity. This article highlights how the GIP receptor expressed by the brain impacts obesity-related pathogenesis.
葡萄糖依赖性胰岛素多肽(GIP)(也称为抑胃肽)是在上消化道产生的激素,响应于食物的摄入、特别是脂肪食物的摄入而分泌到循环中。越来越多的证据支持 GIP 在肥胖中的生理和药理学相关性。在肥胖环境中,内源性 GIP 或其受体的抑制导致能量摄入减少、能量消耗增加或两者兼而有之,最终导致体重减轻。此外,外源性长效 GIP 激动剂的超生理剂量会改变能量平衡并具有显著的抗肥胖作用。这种显著但矛盾的抗肥胖作用主要被认为发生在大脑中。大脑能够调节能量摄入和消耗,并在人类肥胖中起着关键作用。此外,GIP 受体广泛分布于大脑中,包括负责能量稳态的区域。最近的研究揭示了在肥胖背景下大脑中 GIP 受体以前未被充分认识的作用。本文强调了大脑表达的 GIP 受体如何影响与肥胖相关的发病机制。